Blood test after hormone injection for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study uses a special blood test to look for cancer signals (ctDNA) after a hormone injection. The goal is to learn more about how the cancer might progress, which could help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of pancreatic ductal adenocarcinoma (a type of pancreatic cancer).
- Your care team must have decided that surgery to remove the tumor is an option for you.
- You may or may not have had chemotherapy before – both are allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for proteins in the blood that could help doctors tell the difference between pancreatic cancer and non-cancerous pancreatic conditions, such as chronic pancreatitis or benign cysts. By participating, you could help improve early and accurate diagnosis, which may lead to better outcomes for future patients.
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
This study looks at blood tests to find markers that may help detect and monitor pancreatic cancer. It compares people with pancreatic cancer to those with benign pancreatic conditions and healthy volunteers.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.